Drug General Information |
Drug ID |
D02JGD
|
Former ID |
DNCL003105
|
Drug Name |
SKL-10406
|
Indication |
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32]
|
Phase 1 |
[1]
|
Company |
SK Life Science
|
Target and Pathway |
Target(s) |
D(2) dopamine receptor |
Target Info |
Binder |
[2]
|
5-hydroxytryptamine 2A receptor |
Target Info |
Binder |
[2]
|
KEGG Pathway
|
Rap1 signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Gap junction
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Alcoholismhsa04020:Calcium signaling pathway
|
Serotonergic synapse
|
Inflammatory mediator regulation of TRP channels
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Dopamine receptor mediated signaling pathway
|
Nicotine pharmacodynamics pathwayP04374:5HT2 type receptor mediated signaling pathway
|
Reactome
|
Dopamine receptors
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (q) signalling events
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
Genes and (Common) Pathways Underlying Drug Addiction
|
GPCR ligand binding
|
GPCR downstream signaling
|
Nicotine Activity on Dopaminergic NeuronsWP733:Serotonin Receptor 2 and STAT3 Signaling
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
SIDS Susceptibility Pathways
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
GPCRs, Other
|
References |
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032727) |
---|
REF 2 | Bi-directional modulation of BNST neurons by 5-HT: Molecular expression and functional properties of excitatory 5-HT receptor subtypes. Neuroscience. 2009 December 29; 164(4): 1776-1793. |